Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab in corticosteroid-resistant autoimmune inner ear disease
NCT01950312Phase 2Completed
- Sponsor
- XOMA
- Start
- Aug 2013
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gevokizumab in autoimmune inner ear disease (AIED), sponsored by XOMA. Primary endpoint: Improved hearing threshold (PTA or WRS). Started Aug 2013; status: completed.
02
Drugs
gevokizumab
03
Conditions
autoimmune inner ear disease (AIED)
Beyond the preview
Go deeper on NCT01950312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01950312.